https://m.321223.comnone https://m.321223.com/media/xmlelc50/poster_abstract-2557.pdf https://m.321223.com/media/wsnbvqta/通用型car-t产品ct0596及ct1190b的积极临床数据.pdf https://m.321223.com/media/wncfkrfb/��ʾ��-���ֻ�������ע��Һʹ����ѵ����֤��ҽ�ƻ�����������-0720.pdf https://m.321223.com/media/wivjdipc/2023-hy.pdf https://m.321223.com/media/wccjzwma/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b.pdf https://m.321223.com/media/vujmc2eu/green-application-form.pdf https://m.321223.com/media/u1wdz4jn/hkex-eps_20241210_11472656_0.pdf https://m.321223.com/media/tz2paqen/global-offering-2-cn.pdf https://m.321223.com/media/txzffkap/hkex-eps_20221209_10538157_0fan.pdf https://m.321223.com/media/t5zguoik/hkex-eps_20260930_12354322_0.pdf https://m.321223.com/media/syrk40jm/final-carsgen-therapeutics-corporate-deck_oct-28.pdf https://m.321223.com/media/rzmju0v4/ct0596-eha2026-poster-final-1.pdf https://m.321223.com/media/rqfnslii/2024041800870_c.pdf https://m.321223.com/media/pp2bzlw0/�Ƽ�ҩҵ2025Ͷ���߿�����.pdf https://m.321223.com/media/pp2bzlw0/Z6尊龙凯时药业2025投资者盛开日.pdf https://m.321223.com/media/pjrcksuy/global-offering.pdf https://m.321223.com/media/oy2arfcg/poster-1056p.pdf https://m.321223.com/media/otzepuxu/contractual-arrangements-which-are-material-contracts.pdf https://m.321223.com/media/n2ih2b4l/carsgen-therapeutics-2025-investor-day.pdf https://m.321223.com/media/mi3ppjp2/final-�Ƽ�ҩҵ��˾����-oct-28.pdf https://m.321223.com/media/mi3ppjp2/final-Z6尊龙凯时药业公司介绍-oct-28.pdf https://m.321223.com/media/mbijtrcb/final-Z6尊龙凯时药业公司介绍-sept-1.pdf https://m.321223.com/media/malcgk31/green-application-form-cn.pdf https://m.321223.com/media/lgei54pn/global-offering-2.pdf https://m.321223.com/media/kuxd30iu/final-carsgen-therapeutics-corporate-deck_sept-1.pdf https://m.321223.com/media/kolhjqpf/2022-interim-report-cn.pdf https://m.321223.com/media/jyvpmslq/hkex-eps_20260915_12332734_0.pdf https://m.321223.com/media/iznib0sv/c_ham25051660ann-20250904-20250904_1325.pdf https://m.321223.com/media/ghcj2aj4/cn_hkex-eps_20240909_11360645_0.pdf https://m.321223.com/media/gdon4wmr/ct0596-ash-poster-20251110-for-submision.pdf https://m.321223.com/media/fdyfi4ug/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_cn.pdf https://m.321223.com/media/caaamxan/hkex-eps_20260522_12169562_0.pdf https://m.321223.com/media/brtijrlk/2021-annual-report.pdf https://m.321223.com/media/5owm5t4b/global-offering-cn.pdf https://m.321223.com/media/5drbms3p/2024-annual-report-c.pdf https://m.321223.com/media/4tejef2g/2025-interim-report-c.pdf https://m.321223.com/media/4hyptsvx/ct1190b-ps2064_ye-1.pdf https://m.321223.com/media/3byc3vpp/hkex-eps_20230419_10692750_0_hk.pdf https://m.321223.com/media/2w4bh31e/procedures-for-shareholders-to-propose-directors-cn.pdf https://m.321223.com/media/1rjd2yul/hkex-eps_20260410_12102281_0.pdf https://m.321223.com/hk/privacy-policy/ https://m.321223.com/hk/pipeline/ https://m.321223.com/hk/our-approach/technologies/ https://m.321223.com/hk/our-approach/publications/ https://m.321223.com/hk/our-approach/manufacturing/ https://m.321223.com/hk/our-approach/ https://m.321223.com/hk/news/ https://m.321223.com/hk/investors/listing-documents/ https://m.321223.com/hk/investors/ir-contact/ https://m.321223.com/hk/investors/financial-reports/ https://m.321223.com/hk/investors/corporate-governance/ https://m.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ https://m.321223.com/hk/investors/corporate-deck-presentations/ https://m.321223.com/hk/investors/announcements-circulars/ https://m.321223.com/hk/investors/ https://m.321223.com/hk/disclaimer/ https://m.321223.com/hk/contact-us/ https://m.321223.com/hk/careers/join-us/ https://m.321223.com/hk/careers/ https://m.321223.com/hk/about-us/vision-mission-values/ https://m.321223.com/hk/about-us/partnering/ https://m.321223.com/hk/about-us/company-overview/ https://m.321223.com/hk/about-us/ https://m.321223.com/hk/" https://m.321223.com/hk/ https://m.321223.com/en/privacy-policy/ https://m.321223.com/en/pipeline/new-pipeline/mab/kj-c2630/ https://m.321223.com/en/pipeline/new-pipeline/mab/kj-c2527/ https://m.321223.com/en/pipeline/new-pipeline/mab/kj-c2526/ https://m.321223.com/en/pipeline/new-pipeline/mab/ct1390b/ https://m.321223.com/en/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ https://m.321223.com/en/pipeline/new-pipeline/mab/ct0596/ https://m.321223.com/en/pipeline/new-pipeline/mab/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ https://m.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/ https://m.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ https://m.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ct041/ https://m.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ https://m.321223.com/en/pipeline/new-pipeline/ https://m.321223.com/en/pipeline/expanded-access/ https://m.321223.com/en/pipeline/ https://m.321223.com/en/our-approach/technologies/ https://m.321223.com/en/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ https://m.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ https://m.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ https://m.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 https://m.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 https://m.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 https://m.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ https://m.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 https://m.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 https://m.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 https://m.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ https://m.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/ https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=5 https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 https://m.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ https://m.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://m.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://m.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 https://m.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 https://m.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 https://m.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 https://m.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 https://m.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 https://m.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ https://m.321223.com/en/our-approach/publications/?page=5 https://m.321223.com/en/our-approach/publications/?page=2 https://m.321223.com/en/our-approach/publications/?page=1 https://m.321223.com/en/our-approach/publications/20261001/ https://m.321223.com/en/our-approach/publications/20260918/ https://m.321223.com/en/our-approach/publications/20251029/?page=4 https://m.321223.com/en/our-approach/publications/20251029/?page=2 https://m.321223.com/en/our-approach/publications/20251029/?page=1 https://m.321223.com/en/our-approach/publications/20251029/ https://m.321223.com/en/our-approach/publications/20251008/?page=4 https://m.321223.com/en/our-approach/publications/20251008/?page=2 https://m.321223.com/en/our-approach/publications/20251008/?page=1 https://m.321223.com/en/our-approach/publications/20251008/ https://m.321223.com/en/our-approach/publications/20250930/?page=5 https://m.321223.com/en/our-approach/publications/20250930/?page=2 https://m.321223.com/en/our-approach/publications/20250930/?page=1 https://m.321223.com/en/our-approach/publications/20250930/ https://m.321223.com/en/our-approach/publications/20250531/ https://m.321223.com/en/our-approach/publications/20240524/ https://m.321223.com/en/our-approach/publications/20240311/ https://m.321223.com/en/our-approach/publications/20240205/ https://m.321223.com/en/our-approach/publications/20230920/ https://m.321223.com/en/our-approach/publications/20230909/ https://m.321223.com/en/our-approach/publications/20230830/ https://m.321223.com/en/our-approach/publications/20221215/ https://m.321223.com/en/our-approach/publications/20220817/ https://m.321223.com/en/our-approach/publications/20201001/ https://m.321223.com/en/our-approach/publications/20200925/ https://m.321223.com/en/our-approach/publications/20200801/ https://m.321223.com/en/our-approach/publications/20200121/ https://m.321223.com/en/our-approach/publications/20191219/ https://m.321223.com/en/our-approach/publications/20190920/ https://m.321223.com/en/our-approach/publications/20190701/ https://m.321223.com/en/our-approach/publications/20190429/ https://m.321223.com/en/our-approach/publications/20190417/ https://m.321223.com/en/our-approach/publications/20181101/ https://m.321223.com/en/our-approach/publications/20181001/ https://m.321223.com/en/our-approach/publications/20180906/ https://m.321223.com/en/our-approach/publications/20180804/ https://m.321223.com/en/our-approach/publications/20171218/ https://m.321223.com/en/our-approach/publications/20170919/ https://m.321223.com/en/our-approach/publications/20170703/ https://m.321223.com/en/our-approach/publications/20170516/ https://m.321223.com/en/our-approach/publications/20161229/ https://m.321223.com/en/our-approach/publications/ https://m.321223.com/en/our-approach/manufacturing/ https://m.321223.com/en/our-approach/ https://m.321223.com/en/news/20261026/ https://m.321223.com/en/news/20261013/ https://m.321223.com/en/news/20260929/ https://m.321223.com/en/news/20260819/ https://m.321223.com/en/news/20260807/ https://m.321223.com/en/news/20260804/ https://m.321223.com/en/news/20260715/ https://m.321223.com/en/news/20260622/ https://m.321223.com/en/news/20260615/ https://m.321223.com/en/news/20260601/ https://m.321223.com/en/news/20260521/ https://m.321223.com/en/news/20260213/ https://m.321223.com/en/news/20260112/ https://m.321223.com/en/news/20251229/ https://m.321223.com/en/news/ https://m.321223.com/en/investors/listing-documents/ https://m.321223.com/en/investors/ir-contact/ https://m.321223.com/en/investors/financial-reports/ https://m.321223.com/en/investors/corporate-governance/ https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/webcasts/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20261026/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=6 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=6 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ https://m.321223.com/en/investors/corporate-deck-presentations/presentations/ https://m.321223.com/en/investors/corporate-deck-presentations/corporate-deck/ https://m.321223.com/en/investors/corporate-deck-presentations/ https://m.321223.com/en/investors/announcements-circulars/ https://m.321223.com/en/investors/ https://m.321223.com/en/disclaimer/ https://m.321223.com/en/contact-us/ https://m.321223.com/en/careers/join-us/ https://m.321223.com/en/careers/ https://m.321223.com/en/about-us/vision-mission-values/ https://m.321223.com/en/about-us/partnering/ https://m.321223.com/en/about-us/leadership/ https://m.321223.com/en/about-us/company-overview/ https://m.321223.com/en/about-us/ https://m.321223.com/en/ https://m.321223.com/cn/privacy-policy/ https://m.321223.com/cn/pipeline/zevor-cel/ https://m.321223.com/cn/pipeline/satri-cel/ https://m.321223.com/cn/pipeline/new-pipeline/mab/kj-c2630/ https://m.321223.com/cn/pipeline/new-pipeline/mab/kj-c2527/ https://m.321223.com/cn/pipeline/new-pipeline/mab/kj-c2526/ https://m.321223.com/cn/pipeline/new-pipeline/mab/ct1390b/ https://m.321223.com/cn/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ https://m.321223.com/cn/pipeline/new-pipeline/mab/ct0596/ https://m.321223.com/cn/pipeline/new-pipeline/mab/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ https://m.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/ https://m.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ https://m.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ct041/ https://m.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ https://m.321223.com/cn/pipeline/new-pipeline/ https://m.321223.com/cn/pipeline/ https://m.321223.com/cn/our-approach/technologies/ https://m.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=4 https://m.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=2 https://m.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=1 https://m.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ https://m.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ https://m.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ https://m.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 https://m.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 https://m.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 https://m.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ https://m.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ https://m.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/ https://m.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 https://m.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 https://m.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 https://m.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ https://m.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ https://m.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://m.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://m.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 https://m.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 https://m.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 https://m.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 https://m.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 https://m.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 https://m.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ https://m.321223.com/cn/our-approach/publications/20261001/ https://m.321223.com/cn/our-approach/publications/20260918/ https://m.321223.com/cn/our-approach/publications/20251029/ https://m.321223.com/cn/our-approach/publications/20251008/ https://m.321223.com/cn/our-approach/publications/20250930/?page=4 https://m.321223.com/cn/our-approach/publications/20250930/?page=2 https://m.321223.com/cn/our-approach/publications/20250930/?page=1 https://m.321223.com/cn/our-approach/publications/20250930/ https://m.321223.com/cn/our-approach/publications/20250531/ https://m.321223.com/cn/our-approach/publications/20240524/ https://m.321223.com/cn/our-approach/publications/20240311/ https://m.321223.com/cn/our-approach/publications/20240205/ https://m.321223.com/cn/our-approach/publications/20230920/ https://m.321223.com/cn/our-approach/publications/20230909/ https://m.321223.com/cn/our-approach/publications/20230830/ https://m.321223.com/cn/our-approach/publications/20221215/ https://m.321223.com/cn/our-approach/publications/20220817/ https://m.321223.com/cn/our-approach/publications/20201001/ https://m.321223.com/cn/our-approach/publications/20200925/ https://m.321223.com/cn/our-approach/publications/20200801/ https://m.321223.com/cn/our-approach/publications/20200121/ https://m.321223.com/cn/our-approach/publications/20191219/ https://m.321223.com/cn/our-approach/publications/20190920/ https://m.321223.com/cn/our-approach/publications/20190701/ https://m.321223.com/cn/our-approach/publications/20190429/ https://m.321223.com/cn/our-approach/publications/20190417/ https://m.321223.com/cn/our-approach/publications/20181101/ https://m.321223.com/cn/our-approach/publications/20181001/ https://m.321223.com/cn/our-approach/publications/20180906/ https://m.321223.com/cn/our-approach/publications/20180804/ https://m.321223.com/cn/our-approach/publications/20171218/ https://m.321223.com/cn/our-approach/publications/20170919/ https://m.321223.com/cn/our-approach/publications/20170703/ https://m.321223.com/cn/our-approach/publications/20170516/ https://m.321223.com/cn/our-approach/publications/20161229/ https://m.321223.com/cn/our-approach/publications/ https://m.321223.com/cn/our-approach/manufacturing/ https://m.321223.com/cn/our-approach/ https://m.321223.com/cn/news/20260911/ https://m.321223.com/cn/news/20260819/ https://m.321223.com/cn/news/20260807/ https://m.321223.com/cn/news/20260804/ https://m.321223.com/cn/news/20260724/ https://m.321223.com/cn/news/20260722/ https://m.321223.com/cn/news/20260716/ https://m.321223.com/cn/news/20260715/ https://m.321223.com/cn/news/20260615/ https://m.321223.com/cn/news/20260601/ https://m.321223.com/cn/news/20260112/ https://m.321223.com/cn/news/20251230/ https://m.321223.com/cn/news/20251229/ https://m.321223.com/cn/news/ https://m.321223.com/cn/investors/listing-documents/ https://m.321223.com/cn/investors/ir-contact/ https://m.321223.com/cn/investors/financial-reports/ https://m.321223.com/cn/investors/corporate-governance/ https://m.321223.com/cn/investors/corporate-deck-presentations/webcasts/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/通用型car-t产品ct0596及ct1190b的积极临床数据/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=6 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=6 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ https://m.321223.com/cn/investors/corporate-deck-presentations/presentations/ https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=5 https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=4 https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=3 https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=2 https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=1 https://m.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/ https://m.321223.com/cn/investors/corporate-deck-presentations/ https://m.321223.com/cn/investors/announcements-circulars/ https://m.321223.com/cn/investors/ https://m.321223.com/cn/disclaimer/ https://m.321223.com/cn/contact-us/ https://m.321223.com/cn/careers/join-us/ https://m.321223.com/cn/careers/ https://m.321223.com/cn/about-us/vision-mission-values/ https://m.321223.com/cn/about-us/partnering/ https://m.321223.com/cn/about-us/leadership/ https://m.321223.com/cn/about-us/company-overview/ https://m.321223.com/cn/about-us/ https://m.321223.com/cn/ https://m.321223.com/ https://m.321223.com" https://m.321223.com http://m.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html http://m.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html http://m.321223.com/html/web/xinwenzhongxin/fangdaxinwen/< http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103055327044489218.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103054625089966082.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102682494330130434.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102403339000664066.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2101980645155328001.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2101980006543183873.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2101979424646418433.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2100586887281037314.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2099789717976043522.html http://m.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2099789035571171330.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/zhongxingshangye/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/yihangkeji/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/xinshengfeixiang/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/shouhangzhishengji/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/haihangkonggu/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdategang/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdatansu/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/dongbeizhiyao/index.html http://m.321223.com/html/web/touziyuhezuo/shangshigongsi/chengdutancai/index.html http://m.321223.com/html/web/shehuizeren/zhichiguofang/index.html http://m.321223.com/html/web/shehuizeren/yifanashui/index.html http://m.321223.com/html/web/shehuizeren/shehuigongyi/index.html http://m.321223.com/html/web/shehuizeren/jienenghuanbao/index.html http://m.321223.com/html/web/shehuizeren/baozhangjiuye/index.html http://m.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html http://m.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html http://m.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html http://m.321223.com/html/web/guanyuwomen/fangdarongyu/index.html http://m.321223.com/html/web/guanyuwomen/fangdajianjie/index.html http://m.321223.com/html/web/dangjianwenhua/xingfufangda/index.html http://m.321223.com/html/web/dangjianwenhua/qiyelinian/index.html http://m.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html http://m.321223.com/html/web/chengyuandanwei/yiyao/index.html http://m.321223.com/html/web/chengyuandanwei/tansu/index.html http://m.321223.com/html/web/chengyuandanwei/shangye/index.html http://m.321223.com/html/web/chengyuandanwei/hangkong/index.html http://m.321223.com/html/web/chengyuandanwei/gangtie/index.html http://m.321223.com/column/95/ http://m.321223.com/column/94/ http://m.321223.com/column/92/ http://m.321223.com/column/138/ http://m.321223.com/ http://m.321223.com https://www.yzr.com.cn/micro/main/aboutus/63ca0a89b5240a7602621d60 http://m.321223.com https://www.ykfdyy.com/ http://m.321223.com https://www.westair.cn/stcontent/menupage/f9515923-5f75-4801-a3f3-daf09cdbb133/fd170793-0f42-499e-b03a-bc0632fe0cc5/9f991f7f-89e1-4c22-b1c7-411156b46ef0 http://m.321223.com https://www.urumqi-air.com/micro/main/aboutus/641159f50c682c7801e5a149 http://m.321223.com https://www.tianjin-air.com/stcontent/menupage/0bbd75f1-bc38-41c6-95f4-4e3644aa70b8/7c0ff667-57c6-4de5-8e7f-e9fa5b0d4ccb/766eab66-6b64-48f7-b6de-b2ab8c2e8742 http://m.321223.com https://www.nepharm.com.cn/html/web/liaojiewomen/gongsijianjie/index.html http://m.321223.com https://www.luckyair.net/micro/main/aboutus/641d4bbf230c607e69a9a99f http://m.321223.com https://www.jxfangda-steels.com/index/about/id/1.html http://m.321223.com https://www.jdair.net/micro/main/article/64599c7160a9be4d4434c960 http://m.321223.com https://www.hnasatc.edu.cn/xxgk/xxjj.htm http://m.321223.com https://www.hnair.com/guanyuhaihang/hhgs/gsjj/ http://m.321223.com https://www.hnacargo.com/Portal2/AboutUs.aspx http://m.321223.com https://www.gxairlines.com/stdair/tcms?directoryName=foot&fileName=CompanyAndOverview http://m.321223.com https://www.fuzhou-air.cn/micro/main/aboutus/63db6994257effa4641ba390 http://m.321223.com https://www.fddzsteel.com/dg_gywm/dg_qyjj/cindex1.html http://m.321223.com https://www.fd-yy.com/html/web/guanyuwomen/yiyuanjianjie/index.html http://m.321223.com https://www.deerjet.com/about/advantage.html http://m.321223.com https://www.cdcarbon.cn/intro/3.html http://m.321223.com https://www.cd-ts.cn/about/7.html http://m.321223.com https://www.airchangan.com/content/c2aafb9c-c9a1-414e-8182-000a082ff315 http://m.321223.com https://fushuncarbon.com http://m.321223.com http://www.scdesheng.com/ http://m.321223.com http://www.nhi.com.cn/html/web/guanyuwomen/gongsijianjie/index.html http://m.321223.com http://www.hnatechnic.com/html/web/aboutus/gongsijianjie/index.html http://m.321223.com http://www.fangda-specialsteels.com/web/index.aspx http://m.321223.com http://www.3-hospital-cqmu.com http://m.321223.com http://fdtsgs.com http://m.321223.com /html/web/chengyuandanwei/tansu/1952972548200914946.html http://m.321223.com /html/web/chengyuandanwei/tansu/1952971930770006018.html http://m.321223.com /html/web/chengyuandanwei/tansu/1952969997875339266.html http://m.321223.com /html/web/chengyuandanwei/tansu/1952966690133958658.html http://m.321223.com /html/web/chengyuandanwei/hangkong/1953010391426195457.html http://m.321223.com /html/web/chengyuandanwei/hangkong/1953007446785712129.html http://m.321223.com /html/web/chengyuandanwei/gangtie/2062069973823197186.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952982209025204225.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952981773291544577.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952981140610146305.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952980763097620482.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952980411455561730.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952980023696351234.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952978003895705602.html http://m.321223.com /html/web/chengyuandanwei/gangtie/1952977484364046338.html http://m.321223.com